# Test Results: writing/specific-aims.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** writing/specific-aims.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I am drafting a Specific Aims page for a {GRANT_TYPE: e.g., "NIH R01," "NSF CAREER," "foundation grant"} on {RESEARCH_TOPIC}. The funding agency emphasizes {AGENCY_PRIORITIES: e.g., "mechanistic understanding," "translational potential," "innovative methods"}.

My research plan notes:
{YOUR_NOTES: Include the problem, your approach, preliminary data if any, and what each aim will accomplish}

Target length: {LENGTH: e.g., "1 page," "500 words"}

Task: Draft a Specific Aims page with the following structure:

**Opening paragraph (The Hook):**
- First sentence: Establish the problem and its significance (the "so what")
- Knowledge gap: What critical barrier limits progress?
- Your solution: How does your approach address this gap?
- Long-term goal and overall objective for this proposal

**Specific Aims (2-3 typically):**
For each aim:
- State the aim as a clear objective (what you will do)
- Brief rationale (why this aim matters)
- Approach summary (1-2 sentences on how)
- Expected outcome (what you'll learn)

**Closing paragraph:**
- How the aims integrate and build on each other
- Impact statement: what will be possible after this work that isn't possible now?
- Connection to agency mission (if applicable)

Constraints:
- Use ONLY information from my notes—do not fabricate preliminary data, citations, or capabilities
- Flag any claims that need preliminary data support as [NEEDS PRELIM DATA]
- Flag any citations needed as [CITE]
- Keep within target length
- Use active, confident language—avoid excessive hedging
- Make aims concrete and achievable within the funding period

Output format: Formatted aims page with section headers. Flag gaps for my attention.

Context: I am drafting a Specific Aims page for an NIH R21 (exploratory/developmental) on microbiome biomarkers for colorectal cancer screening. The funding agency emphasizes innovative approaches and high-risk/high-reward research.

My research plan notes:

Problem: Colorectal cancer is the 2nd leading cause of cancer death in the US. Colonoscopy screening is effective but has low compliance (~60%). Non-invasive biomarkers could improve screening rates. Current fecal tests (FIT, Cologuard) have limited sensitivity for adenomas.

My approach: Develop a microbiome-based classifier that detects precancerous adenomas from stool samples. Leverage the known microbiome changes in CRC to detect disease earlier.

Preliminary data:
- Pilot study with 25 adenoma cases, 25 controls
- 16S sequencing identified 12 differentially abundant taxa
- Random forest classifier achieved 78% AUC (needs validation)

Aim 1: Validate and refine the microbiome classifier in an independent cohort
- Partner with GI clinic for prospective sample collection
- Target 100 adenoma cases, 100 controls
- Test classifier performance and refine features

Aim 2: Integrate microbiome data with existing biomarkers (FIT)
- Hypothesis: combined model outperforms either alone
- Collect FIT results alongside microbiome samples
- Build integrated classifier

Innovation: First study to combine microbiome signatures with established screening biomarkers for adenoma detection

My lab: expertise in microbiome bioinformatics, machine learning, established GI collaborations

Target length: 1 page (R21 limit)
```

## Model Output
```
# SPECIFIC AIMS

Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, yet it is largely preventable through early detection of precancerous adenomas. Colonoscopy remains the gold standard for screening, but patient compliance hovers near 60% [CITE], leaving millions at risk due to procedural burden, cost, and access barriers. Non-invasive stool-based tests offer a promising alternative; however, current options—the fecal immunochemical test (FIT) and multi-target stool DNA testing (Cologuard)—demonstrate limited sensitivity for adenoma detection, the critical window for intervention [CITE]. **The fundamental barrier to progress is the absence of a validated, non-invasive biomarker capable of reliably identifying precancerous lesions before malignant transformation.** The gut microbiome undergoes measurable compositional shifts during CRC development [CITE], yet microbiome-based classifiers have not been rigorously validated for adenoma detection, nor integrated with established screening biomarkers to maximize diagnostic performance. Our **long-term goal** is to develop a clinically deployable, stool-based microbiome test that improves early CRC detection at the population level. The **overall objective of this R21** is to validate a microbiome-derived classifier for adenoma detection and determine whether integrating microbiome signatures with FIT results produces a superior combined diagnostic model. Our pilot data in 50 participants (25 adenoma cases, 25 controls) identified 12 differentially abundant taxa and yielded a random forest classifier with 78% AUC, establishing proof-of-concept and justifying this exploratory investigation. We will pursue this objective through two specific aims:

---

**Aim 1: Validate and refine a microbiome-based classifier for adenoma detection in an independent prospective cohort.**

*Rationale:* Our pilot classifier [NEEDS PRELIM DATA — consider adding power analysis justification for n=100/group] requires independent validation before clinical translation can be considered. Prospective collection will also capture real-world microbiome variability not represented in pilot data.

*Approach:* In partnership with our established GI clinic collaborators, we will prospectively enroll 100 adenoma cases and 100 colonoscopy-confirmed controls, collect stool samples prior to bowel preparation, and perform 16S rRNA sequencing. We will test classifier performance in this independent cohort and apply feature refinement to improve generalizability.

*Expected Outcome:* A validated microbiome classifier with defined sensitivity, specificity, and AUC benchmarks, and an optimized feature set suitable for integration in Aim 2. We expect this aim to establish whether the microbiome signal is robust across a larger, independent population.

---

**Aim 2: Develop and evaluate an integrated classifier combining microbiome signatures with FIT results for adenoma detection.**

*Rationale:* FIT and microbiome biomarkers likely capture complementary biological signals—occult bleeding and microbial dysbiosis, respectively. We hypothesize that a combined model will outperform either biomarker alone, particularly for adenomas that are FIT-negative. **This represents the first systematic integration of microbiome signatures with an established screening biomarker for adenoma detection.**

*Approach:* Using the Aim 1 cohort, we will collect concurrent FIT results and build a multivariate integrated classifier using machine learning approaches developed in our laboratory. Model performance will be compared against FIT alone, microbiome alone, and published Cologuard benchmarks using cross-validation and bootstrapped confidence intervals.

*Expected Outcome:* Quantification of the additive diagnostic value of microbiome data over FIT, and a combined classifier ready for prospective evaluation in a future R01. [NEEDS PRELIM DATA — if available, any pilot data suggesting FIT-negative adenomas show microbiome signal would strongly strengthen this aim's rationale]

---

**Integration and Impact:** Aim 1 provides the validated microbiome classifier that serves as the foundation for Aim 2; together, the aims follow a logical progression from validation to innovation. Upon completion, this work will establish whether a microbiome-augmented screening strategy can detect adenomas that current non-invasive tests miss—directly addressing a critical gap in CRC prevention. If successful, these findings will provide the evidentiary basis for a fully powered R01 clinical trial and position a new class of non-invasive screening tools for development. This proposal aligns directly with NIH's emphasis on high-risk, high-reward research: the potential to meaningfully shift CRC screening paradigms justifies the exploratory investment, and our preliminary data and established clinical partnerships mitigate key feasibility risks.

---

> **⚑ Author Flags — Review Before Submission:**
> 1. **[NEEDS PRELIM DATA]** Aim 1: Add a brief power/sample size justification for n=100/group to preempt reviewer concern.
> 2. **[NEEDS PRELIM DATA]** Aim 2: Any pilot signal showing FIT-negative adenomas have distinct microbiome profiles would substantially strengthen the rationale. If unavailable, consider softening the hypothesis slightly.
> 3. **[CITE ×3]** Add citations for: (a) colonoscopy compliance ~60%, (b) FIT/Cologuard adenoma sensitivity limitations, (c) microbiome shifts in CRC development.
> 4. **Innovation claim** ("first study to combine…"): Conduct a targeted literature search to confirm this claim is defensible before submission.
> 5. **R21 fit:** Confirm your institute's R21 guidelines—some require explicit acknowledgment of the exploratory/developmental nature and a clear path to future funding (the closing paragraph addresses this, but verify it meets your program officer's expectations).
```

## Assessment
_To be completed by a human reviewer. Do not mark Pass without reading the output._

### Task Achievement
- **Achieved:** [Yes / No / Partial]
- **Notes:**

### Constraint Compliance
- **All constraints respected:** [Yes / No]
- **Violations noted:**

### Failure Modes
- **Failure modes observed:** [None / list]
- **Mitigation effectiveness:**

### Output Format
- **Format correct:** [Yes / No]
- **Deviations:**

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
